GPR55 / TRPV1 / adenosine transport (multi-target)

Class

Cannabidiol (multi-target cannabinoid, non-CB1/CB2-mediated)

Cannabidiol (CBD) is a plant-derived cannabinoid that produces its effects largely without engaging the classical cannabinoid receptors CB1 and CB2, which mediate the psychoactive effects of tetrahydrocannabinol. Instead, CBD modulates several distinct targets: GPR55, an orphan G-protein-coupled receptor implicated in calcium signaling and cell proliferation; TRPV1, an ion channel involved in pain and thermal sensation; and equilibrative nucleoside transporters, which normally clear the signaling molecule adenosine from the extracellular space. By antagonizing GPR55, desensitizing TRPV1, and inhibiting adenosine reuptake, CBD can dampen neuronal excitability, reduce nociceptive signaling, and raise extracellular adenosine levels, which itself has calming and anti-inflammatory actions through adenosine receptors. This combination allows CBD to influence excitability, inflammation, and pain processing through mechanisms separate from the receptors responsible for cannabis intoxication. The biological rationale for this profile is to achieve therapeutic modulation of neuronal and immune signaling while avoiding the psychoactivity and dependence liability associated with direct CB1 agonism. This multi-target, non-intoxicating mechanism is broadly relevant to conditions involving abnormal neuronal excitability, chronic pain, and inflammatory processes, including certain seizure disorders and inflammatory or neuropathic pain states.